Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Stock Information for Avalo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avalo Therapeutics Inc.

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
Avalo Therapeutics to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.